Home›Research›Compare›BPC-157 vs Sermorelin
Peptide ComparisonBPC-157 vs Sermorelin
BPC-157
Body Protection Compound 157
Half-life: Under 30 minutes (plasma); no human PK data
638 providers listed
Sermorelin
GHRH 1-29
Half-life: 10–20 minutes
449 providers listed
BPC-157 and Sermorelin target different goals — BPC-157 for tissue repair across tendon, muscle, nerve, and gut — most broadly studied recovery peptide, Sermorelin for pulsatile GH release via direct GHRH receptor agonism at the pituitary. They're compared here for reference, not as direct substitutes.
BPC-157
Half-life
Under 30 minutes (plasma); no human PK data
Sermorelin
Half-life
10–20 minutes
BPC-157 and Sermorelin target different goals — BPC-157 for Tissue Repair, Sermorelin for GH / IGF Axis. They're compared here for reference; there isn't a single “better” choice between them.
BPC-157
Sermorelin
BPC-157
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
Unilateral Adrenalectomy, and the Stable Pentadecapeptide BPC 157 as Therapy in Rats-A Cytoprotection Approac…
Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury.
BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase.
+10 more
Sermorelin
The GH response to low-dose bolus growth hormone-releasing hormone (GHRH(1-29)NH2) is attenuated in patients…
The relative roles of continuous growth hormone-releasing hormone (GHRH(1-29)NH2) and intermittent somatostat…
A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodyb…
About BPC-157
BPC-157 is believed to accelerate angiogenesis and upregulate growth hormone receptors locally at injury sites. It appears to promote fibroblast migration and collagen synthesis, contributing to faster tissue remodelling. Animal studies suggest systemic effects via modulation of the dopaminergic and serotonergic systems, though human data remain limited.
About Sermorelin
Sermorelin is a synthetic analogue of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). It binds to GHRH receptors on pituitary somatotrophs, stimulating pulsatile GH secretion in a physiological pattern that preserves the natural hypothalamic-pituitary feedback axis — contrasting with direct GH administration. Downstream IGF-1 elevation mediates many of its body composition, tissue-repair, and sleep quality effects.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
BPC-157
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
global — WADA
BPC-157 is on the WADA Prohibited List at all times (S0, Non-Approved Substances), effective 1 January 2022. It has no FDA approval and no adequate human clinical trial.
sourceSermorelin
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
Sermorelin clinical protocols measure IGF-1 as the primary marker of GH axis response. Fasting glucose and insulin are standard baseline assessments given GH's effect on insulin sensitivity.
BPC-157
GHK-Cu
Research suggests GHK-Cu and BPC-157 may produce complementary tissue repair and anti-inflammatory effects when combined. GHK-Cu is studied for copper-dependent collagen synthesis and antioxidant gene activation, while BPC-157 supports angiogenesis and growth factor expression.
TB-500
Research suggests BPC-157 and TB-500 may produce enhanced tissue repair effects when combined. BPC-157 is studied for angiogenesis and gut-protective properties, while TB-500 promotes actin assembly and cell migration — complementary mechanisms in healing models.
Anticoagulants / blood thinners
Research notes that BPC-157 promotes angiogenesis and may influence platelet and vascular function in healing models. Combined use with anticoagulant medications may warrant monitoring. Consult your prescriber before combining.
Sermorelin
Ipamorelin
Research suggests Sermorelin and Ipamorelin may produce complementary growth hormone release effects when combined. Sermorelin acts as a GHRH analogue via pituitary receptors, while Ipamorelin acts via ghrelin receptors — dual-pathway stimulation studied in GH optimization research.
BPC-157
Sermorelin
Where to source these peptides
BPC-157
638 listed
Browse directory →
Providers offeringSermorelin
449 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
Related Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated August 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). BPC-157 vs Sermorelin — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/bpc-157/sermorelin